| Literature DB >> 32054466 |
Shuang Liu1, Wenya Hu1, Zhiwen Wang1, Tao Chen2.
Abstract
Riboflavin (RF) and its active forms, the cofactors flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), have been extensively used in the food, feed and pharmaceutical industries. Modern commercial production of riboflavin is based on microbial fermentation, but the established genetically engineered production strains are facing new challenges due to safety concerns in the food and feed additives industry. High yields of flavin mononucleotide and flavin adenine dinucleotide have been obtained using whole-cell biocatalysis processes. However, the necessity of adding expensive precursors results in high production costs. Consequently, developing microbial cell factories that are capable of efficiently producing flavin nucleotides at low cost is an increasingly attractive approach. The biotechnological processes for the production of RF and its cognate cofactors are reviewed in this article.Entities:
Keywords: Biotechnology; Flavin cofactor; Riboflavin
Year: 2020 PMID: 32054466 PMCID: PMC7017516 DOI: 10.1186/s12934-020-01302-7
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Fig. 1Chemical structure and nomenclature of flavins
Fig. 2Schematic overview of the relevant pathways for flavin production. (Pathways) PP pathway, the pentose phosphate pathway; TCA, the tricarboxylic acid cycle; EMP, the Embden–Meyerhof pathway/glycolysis; ED, the Entner–Doudoroff pathway. (Metabolites) G6P, Glucose-6-phosphate; GAP, Glyceraldehyde 3-phosphate; 3GP, Glycerate 3-phosphate; PYR, Pyruvate; OAA, Oxaloacetate; 6-Pgdl, 6-Phospho-d-glucono-1,5-lactone; Gluconate-6P, 6-Phospho-d-gluconate; PRPP, Phosphoribosylpyrophosphate; Ru5P, Ribulose 5-phosphate; GTP, Guanosine 5′-triphosphate; Gly, Glycine; GTP, guanosine 5′-triphosphate; DHPB, L-3,4-Dihydroxybutan-2-one 4-phosphate; DARPP, 2,5-Diamino-6-(1-d-ribosylamino)pyrimidin-4(3H)-one 5′-phosphate; AFAPP, 2-Amino-5-formylamino-6-(5-phospho-d-ribosylamino)pyrimidin-4(3H)-one; DArPP, 2,5-Diamino-6-(1-d-ribitylamino)pyrimidin-4(3H)-one 5′-phosphate; ARPP, 5-Amino-6-(ribosylamino)-2,4-(1H,3H)-pyrimidinedione 5′-phosphate; ArPP, 5-Amino-2,6-dioxy-4-(5′-phospho-d-ribitylamino)pyrimidine; ArP, 5-Amino-6-(1-d-ribitylamino)uracil; DrL, 6,7-Dimethyl-8-(D-ribityl)lumazine; RF, Riboflavin; FMN, Flavin mononucleotide; FAD, Flavin adenine dinucleotide; (Enzymes that catalyze the Reactions) I, GTP cyclohydrolase II, (EC: 3.5.4.25); ①, GTP cyclohydrolase IIa, (EC: 3.5.4.29); ②, AFAPP deformylase (EC: 3.5.1.102); II & III, deaminase (EC: 3.5.4.26) & reductase (EC: 1.1.1.193); ③ & ④, reductase (EC: 1.1.1.302) & deaminase (EC: 5.4.99.28); IV, 5-amino-6-(5-phospho-d-ribitylamino)uracil phosphatase (EC: 3.1.3.104); V, DHPB synthase (EC: 4.1.99.12); VI, 6,7-dimethyl-8-ribityllumazine synthase (EC: 2.5.1.78); VII, RF synthase (EC: 2.5.1.9) VIII, RF kinase; IX, FMN adenylyltransferase/FAD synthetase
Metabolic engineering for overproduction of RF by gene manipulation
| Organism | GOIa and Manipulationb | Riboflavin titersc | Improvement | References |
|---|---|---|---|---|
| Overexpression of the RF synthesis pathway | ||||
| | c−1 | 25% | [ | |
| | 0.4–0.7 | Tenfold | [ | |
| | 4.3 | 27% | [ | |
| | 0.327 | 3.1-fold | [ | |
| | 0.229 | – | [ | |
| | 15.3 | 16-fold | [ | |
| | 16.4 | 62-fold | [ | |
| | 0.331 | 1.44-fold | [ | |
| | 0.024 | – | [ | |
| Overexpression of the purine biosynthesis pathway | ||||
| | ~ 5.1 | 31% | [ | |
| | 0.827 | Threefold | [ | |
| | 0.05 | 80% | [ | |
| | ~ 0.12c−2 | 40% | [ | |
| | 24.28 mg/gc−3 | 12-fold | [ | |
| | Ag | 0.228 | Tenfold | [ |
| | 7.5 mg/gc−4 | 6.5 | [ | |
| | ( | 0.388 | 72% | [ |
| | 3.49 mg/L | 50% | [ | |
| Optimization of the central carbon metabolism | ||||
| | ~ 0.8 | 25% | [ | |
| | 15.7 | 39% | [ | |
| | 13.36 | 27.8% | [ | |
| | ~ 13 | ~ 28% | [ | |
| | 0.56 | – | [ | |
| Enhanced synthesis of glycine | ||||
| | ~ 16 mg/gc−4 | Ninefold | [ | |
| | 9.6 mg/gc−4 | Tenfold | [ | |
| | ~ 0.15 | 30% | [ | |
| Other strategies | ||||
| | 12.3 | 38% | [ | |
| | HSPs+ | ~ 0.3–0.35 | 23–66% | [ |
aGOI represents the gene of interest. ribA, DHPB synthase; RIB1, GTP cyclohydrolase II; RIB7, RF synthase; RIB3, DHPB synthase; purF, PRPP amidotransferase; purR, purine repressor PurR; AGR371C and AGL080C, PRPP synthetases; prs, PRPP synthetase; purF, PRPP amidotransferase; AER117W, IMP dehydrogenase; ADE4, PRPP amidotransferase; SHM1 and SHM2, serine hydroxymethyltransferase; AgURA3, orotidine-5′-phosphate decarboxylase; zwf, glucose-6-phosphate dehydrogenase; gnd, 6-phosphogluconate dehydrogenase; fbp, fructose-1,6-bisphosphatase; pckA, phosphoenolpyruvate carboxykinase; gapB, glyceraldehyde-3-phosphate dehydrogenase; ccpN, gluconeogenic repressor CcpN; pgi, glucose-6-phosphate isomerase; edd, phosphogluconate dehydratase; eda, multifunctional 2-keto-3-deoxygluconate 6-phosphate aldolase and 2-keto-4-hydroxyglutarate aldolase and oxaloacetate decarboxylase; GLY1, threonine aldolase; SHM2, serine hydroxymethyltransferase; AGX1, alanine-glyoxylate aminotransferase; cydC, cytochrome bd oxidase; HSPs, heat shock proteins; folE, GTP cyclohydrolase I
b“+”indicates gene over-expression; “−” indicates gene downregulation; “Δ” indicates gene knockout; “*” indicates gene mutation
cThe maximum RF titer of the engineered strains. Unit: g/L unless otherwise specified; c−1, Strain VB2XL1 produced up to 25% more RF as compared to its parent strain RB50::[pRF69]n::[pRF93]m Ade; c−2, total (intracellular +extracellular) RF concentration; c−3, mg/g of biomass; c−4, mg/g mycelium